Marie‐Sarah Dilhuydy

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 410 citations

Medicine, Immunology, Pharmacotherapy +12

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien et al. · Haematologica · 2017 · 258 citations · Full text

Medicine, Oncology, Pharmacology +15

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

Jennifer R. Brown, Javid J. Moslehi, Michael S. Ewer et al. · British Journal of Haematology · 2018 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

Susan O’Brien, Peter Hillmen, Steven Coutré et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 81 citations · Full text

Medicine, Hematology, Pharmacology +17

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

Thomas J. Kipps, Graeme Fraser, Steven Coutré et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 45 citations · Full text

Medicine, Molecular Genetics, Oncology +17